Adalimumab and number of previous biological disease-modifying antirheumatic drugs as predictive factors for the development of immune-mediated skin lesions

Martins, A.; Oliveira, D. Santos; Martins, F. R.; Nicolau, R.; Pinheiro, F. Oliveira; Rato, M.; Bernardo, A.; Pimenta, S.; Bernardes, M.; Costa, L.

http://hdl.handle.net/10400.1/26910

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
ADALIMUMAB AND NUMBER OF PREVIOUS BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AS PREDICTIVE FACTORS FOR THE DEVELOPMENT OF IMMUNE-MEDIATED SKIN LESIONS.pdf		240.85 KB	Adobe PDF	Download

Send Feedback

Authors

Pinheiro, F. Oliveira

Abstract(s)

Treatment of inflammatory rheumatic diseases has dramatically changed with the introduction of biologic disease modifying anti-rheumatic drugs (bDMARDs). However, these drugs aren’t exempt from risks and skin lesions are the most frequent adverse reactions. Among the possible adverse skin reactions, immune-mediated skin lesions (IMSL) may occur. Risk factors associated with the occurrence of IMSL in rheumatic patients under bDMARDs are poorly known and studied.